Exact Sciences and Jefferson Health are collaborating to conduct research on a new blood-based, multi-cancer earlier detection (MCED) test, the company announced recently.

According to a release, the joint effort will engage primary care and specialty providers, care coordinators and patients from diverse populations across the more than 100 primary practices in the Jefferson system. It aims to evaluate MCED test safety and efficacy and help determine how to facilitate the implementation of effective MCED testing in the future.

“We share in Jefferson’s deep commitment to building a patient and provider experience that addresses the needs of all populations, including the underserved and vulnerable, so that earlier cancer detection can have the greatest impact,” Exact Sciences CEO Kevin Conroy said in a statement.

Jefferson Healthy also plans to participate in Exact Sciences’ FDA registration study for its MCED test.